Down myeloid disorders: a paradigm for childhood preleukaemia and leukaemia and insights into normal megakaryopoiesis.

[1]  A. F. Cunha,et al.  An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis , 2006, Nature Genetics.

[2]  Sandra A. Moore,et al.  Activating alleles of JAK3 in acute megakaryoblastic leukemia. , 2006, Cancer cell.

[3]  Eero Pukkala,et al.  Cancer incidence of persons with down syndrome in Finland: A population‐based study , 2006, International journal of cancer.

[4]  R. Reeves,et al.  Understanding the Basis for Down Syndrome Phenotypes , 2006, PLoS genetics.

[5]  Aravind Subramanian,et al.  Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[6]  P. Vyas,et al.  GATA1-Mediated Megakaryocyte Differentiation and Growth Control Can Be Uncoupled and Mapped to Different Domains in GATA1 , 2005, Molecular and Cellular Biology.

[7]  D. Webb.  Optimizing therapy for myeloid disorders of Down syndrome , 2005, British journal of haematology.

[8]  Dean Nizetic,et al.  An Aneuploid Mouse Strain Carrying Human Chromosome 21 with Down Syndrome Phenotypes , 2005, Science.

[9]  J. Crispino,et al.  Differential requirements for the activation domain and FOG-interaction surface of GATA-1 in megakaryocyte gene expression and development. , 2005, Blood.

[10]  G. Blobel,et al.  FOG‐1 recruits the NuRD repressor complex to mediate transcriptional repression by GATA‐1 , 2005, The EMBO journal.

[11]  Jeroen Krijgsveld,et al.  GATA‐1 forms distinct activating and repressive complexes in erythroid cells , 2005, The EMBO journal.

[12]  A. Cantor.  GATA Transcription Factors in Hematologic Disease , 2005, International journal of hematology.

[13]  S. Orkin,et al.  Developmental stage–selective effect of somatically mutated leukemogenic transcription factor GATA1 , 2005, Nature Genetics.

[14]  S. Day,et al.  Mortality and causes of death in persons with Down syndrome in California. , 2005, Developmental medicine and child neurology.

[15]  P. Vyas,et al.  GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder , 2005, British journal of haematology.

[16]  J. Taub,et al.  Down syndrome, drug metabolism and chromosome 21 , 2005, Pediatric blood & cancer.

[17]  A. Zipursky,et al.  Distinct gene signatures of transient and acute megakaryoblastic leukemia in Down syndrome , 2004, Leukemia.

[18]  P. Vyas,et al.  Natural history of GATA1 mutations in Down syndrome. , 2004, Blood.

[19]  M. Greaves,et al.  Leukemia in twins: lessons in natural history. , 2003, Blood.

[20]  M. L. Beau,et al.  Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome , 2002, Nature Genetics.

[21]  P. Vyas,et al.  Inositol polyphosphate 4-phosphatase type I regulates cell growth downstream of transcription factor GATA-1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[22]  M. Siimes,et al.  Peripheral blood cell counts in infants with Down's syndrome , 1996, Clinical genetics.

[23]  S. Nasim,et al.  A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children’s Oncology Group (COG) study POG-9481 , 2006 .